Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Halozyme ( (HALO) ) is now available.
On December 4, 2025, Halozyme Therapeutics’ Board approved a performance-based restricted stock unit grant for CEO Dr. Helen Torley, aimed at incentivizing her to drive company growth. The grant’s vesting depends on achieving specific stock price targets over four years, with a retention component requiring Dr. Torley’s continued employment.
The most recent analyst rating on (HALO) stock is a Buy with a $71.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.
Spark’s Take on HALO Stock
According to Spark, TipRanks’ AI Analyst, HALO is a Outperform.
Halozyme’s overall stock score is driven by strong earnings call results and strategic corporate events, which highlight robust growth prospects and strategic positioning. Financial performance is solid but tempered by high leverage. Technical analysis indicates short-term bearish momentum, which may present a buying opportunity if fundamentals remain strong.
To see Spark’s full report on HALO stock, click here.
More about Halozyme
Halozyme Therapeutics, Inc. operates in the biotechnology industry, focusing on developing and commercializing products that enhance the delivery of biologics. The company is known for its proprietary drug delivery technology, which aims to improve patient experiences and outcomes.
Average Trading Volume: 2,228,590
Technical Sentiment Signal: Buy
Current Market Cap: $7.45B
Learn more about HALO stock on TipRanks’ Stock Analysis page.